# Star Therapeutics

**Canonical:** https://apis.io/providers/star-therapeutics/  
**Website:** https://star-therapeutics.com/  
**APIs profiled:** 9

Star Therapeutics is a clinical-stage biotechnology company headquartered at 201 Haskins Way in South San Francisco, California, that transforms the lives of patients with serious diseases by discovering and developing best-in-class antibody therapies, with an initial focus on hematology and immunology. It operates a hub-and-spoke model, building a family of companies that each pursue a distinct area of novel biology, and it develops each programme under a pipeline-in-a-product strategy in which a single antibody is advanced across multiple related indications rather than one. The company emerged from stealth in February 2022 having raised $100 million since inception, added a $90 million round in September 2023, and closed an oversubscribed $125 million Series D in September 2025 to move its lead asset into a registrational programme. Its two named spokes are Vega Therapeutics, whose VGA039 is a first-in-class monoclonal antibody against Protein S developed as a subcutaneous therapy for von Willebrand disease and other bleeding disorders, and Electra Therapeutics, which targets SIRP proteins with ELA-026 in secondary hemophagocytic lymphohistiocytosis. VGA039 has received FDA Orphan Drug, Fast Track, Rare Pediatric Disease and Breakthrough Therapy designations; Incyte completed its acquisition of Vega Therapeutics, a wholly owned subsidiary of Star Therapeutics, in July 2026. Star Therapeutics runs no developer program and publishes no product API, developer portal, or API documentation. The only machine-readable surface reachable without credentials is the WordPress REST content API behind star-therapeutics.com, catalogued here.

## Kin Score — 30.9 / 100 (thin)

Scored 2026-08-12 under rubric 0.11.0. Trend: flat (+0.0 from 30.9).

| Facet | Score |
|---|---|
| Discoverability | 81.5 |
| Contract Quality | 58.2 |
| Governance | 11.5 |
| Operational Transparency | 0.0 |
| Developer Ergonomics | 12.5 |
| Commercial Clarity | 21.1 |

Regulatory layer — **Health**: 31.3 (matched via tags).

## Agent readiness — 36.3 (agent-ready)

| Dimension | Value |
|---|---|
| Spec Presence | yes |
| Agentic Access | no |
| MCP Server | no |
| Auth Clarity | yes |
| Idempotency | no |
| Error Semantics | documented |
| OpenAPI Examples | verified |
| Rate Limit Signal | no |
| Event Surface Described | no |
| Agent Skills | derived |
| Well Known Catalog | no |
| Consent Identity | no |
| Agent Card | no |
| Dry Run Mode | no |

## APIs (9)

- **Star Therapeutics Comments API** — Comment collection. Registered and reachable, but empty — no post on this deployment carries comments.
- **Star Therapeutics Custom Types API** — Avada theme custom post types (avada_faq, avada_portfolio). Registered and anonymously reachable, but both report zero published items.
- **Star Therapeutics Discovery API** — Route, type, taxonomy and status discovery documents.
- **Star Therapeutics Media API** — Media library (661 attachments at harvest time).
- **Star Therapeutics Oembed API** — oEmbed 1.0 provider endpoint for star-therapeutics.com URLs.
- **Star Therapeutics Pages API** — Corporate pages (11 published at harvest time).
- **Star Therapeutics Posts API** — News archive — press releases, news coverage and scientific presentations (28 published at harvest time).
- **Star Therapeutics Search API** — Cross-content search across published objects.
- **Star Therapeutics Taxonomy API** — Categories and tags. Five categories are registered; the post_tag taxonomy is registered but empty.

## Security (2)

- **Star Therapeutics Authentication** — 0 schemes
- **Star Therapeutics Domain Security** — TLSv1.3 · DMARC

## Tags

Company, biotechnology, pharmaceuticals, hematology, immunology, rare-disease, antibody-therapeutics, clinical-trials, life-sciences, content-api

---

Profiled by [API Evangelist](https://apievangelist.com) and published on [APIs.io](https://apis.io/providers/star-therapeutics/). Scores are computed from the provider's own public artifacts under a published rubric.